Innovative Leukemia Stem Cell Technique Enhances Relapse Prediction in AML Patients
A groundbreaking leukemia stem cell-based assay improves relapse prediction accuracy in AML patients, outperforming traditional methods and enabling better post-transplant management.
A recent study has demonstrated that an assay utilizing leukemia stem cells (LSCs) can significantly improve the prediction of disease relapse in patients with acute myeloid leukemia (AML). This LSC-based method outperforms the traditional multiparameter flow cytometry (MFC) approaches, offering a more accurate tool to assess measurable residual disease (MRD). The research, published online on August 23, 2025, in Bone Marrow Transplantation, involves an in-depth analysis of 360 AML patients who underwent allogeneic transplantation between July 2018 and November 2019.
In the study, Si-Qi Li from Peking University People's Hospital and colleagues examined the predictive power of the LSC-based assay compared to conventional MFC-MRD testing. They found that patients with positive MRD based on CD34+CD38− cocktail+ LSCs (≥0.004%) exhibited a substantially higher five-year cumulative relapse incidence (49.7%) compared to those with lower levels (8.5%). These patients also showed worse leukemia-free survival (48.2% vs. 84.4%) and overall survival rates (59.7% vs. 82.8%).
Similarly, traditional MFC-MRD detection was associated with increased relapse risk and decreased survival, but the LSC-based assay demonstrated superior sensitivity and accuracy. The median interval from LSC positivity to relapse was also longer (144 days) compared to traditional MRD markers (65 days), providing a valuable window for intervention.
The findings suggest that incorporating LSC-based MRD assessment could enhance relapse prediction and management strategies for AML patients post-transplant. The authors advocate for the adoption of this method in clinical practice, supported by long-term follow-up data and its high performance metrics, such as a C-index of 0.72 and Youden index of 0.44.
Overall, this advancement represents a promising step forward in AML treatment, helping clinicians better identify high-risk patients and tailor post-treatment strategies accordingly.
For more details, see the original study: Si-Qi Li et al., Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study, Bone Marrow Transplantation (2025). DOI: 10.1038/s41409-025-02699-8
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Exploring the Surprising Role of Protein Aggregates in Brain Disease
New research uncovers how protein aggregates disrupt RNA processing in neurodegenerative diseases caused by GGC repeat expansions, offering promising therapeutic targets.
Silent Night: Understanding and Addressing Snoring Through Anatomy
Discover how understanding the anatomy of the airway can lead to effective, non-invasive solutions for snoring and improve sleep quality and health.
Supporting Housing as a Cost-Effective Solution for Homelessness and Opioid Crisis
Supporting housing for homeless individuals with opioid use disorder is a cost-effective strategy that saves lives and improves health outcomes, according to Stanford research. This approach offers a humane and economically sound solution to homelessness and the opioid crisis.
At-Home Cervical Cancer Tests: An Emerging Alternative to Pap Smears
A new FDA-approved at-home cervical cancer test offers a less invasive, convenient screening option for women, complementing traditional Pap smears and improving access to cervical health care.